83 related articles for article (PubMed ID: 17591826)
1. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.
Fishman MN; Tomshine J; Fulp WJ; Foreman PK
PLoS One; 2015; 10(4):e0120877. PubMed ID: 25830512
[TBL] [Abstract][Full Text] [Related]
3. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
Zurita AJ; Jonasch E; Wang X; Khajavi M; Yan S; Du DZ; Xu L; Herynk MH; McKee KS; Tran HT; Logothetis CJ; Tannir NM; Heymach JV
Ann Oncol; 2012 Jan; 23(1):46-52. PubMed ID: 21464158
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
Dubey S; Jänne PA; Krug L; Pang H; Wang X; Heinze R; Watt C; Crawford J; Kratzke R; Vokes E; Kindler HL
J Thorac Oncol; 2010 Oct; 5(10):1655-61. PubMed ID: 20736856
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
Qiu YQ; Zhou J; Kang XS; Shen-Tu JZ; Ding LM; Tan FL; Guo J; Li LJ
Afr J Tradit Complement Altern Med; 2012; 9(3):431-9. PubMed ID: 23983378
[TBL] [Abstract][Full Text] [Related]
7. Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications.
Li J; Zhang L; Ge T; Liu J; Wang C; Yu Q
Drug Des Devel Ther; 2024; 18():829-843. PubMed ID: 38524877
[TBL] [Abstract][Full Text] [Related]
8. Renal cell carcinoma and the use of sorafenib.
Larkin JM; Eisen T
Ther Clin Risk Manag; 2006 Mar; 2(1):87-98. PubMed ID: 18360584
[TBL] [Abstract][Full Text] [Related]
9. Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma.
Ye DW; Zhang HL
Onco Targets Ther; 2014; 7():925-35. PubMed ID: 24944516
[TBL] [Abstract][Full Text] [Related]
10. A robust primary liver cancer subtype related to prognosis and drug response based on a multiple combined classifying strategy.
Deng J; Lai G; Zhang C; Li K; Zhu W; Xie B; Zhong X
Heliyon; 2024 Feb; 10(3):e25570. PubMed ID: 38352751
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a Novel Template, 7-Substituted 7-Deaza-4'-Thioadenosine Derivatives as Multi-Kinase Inhibitors.
Mashelkar KK; Byun WS; Ko H; Sung K; Tripathi SK; An S; Yum YA; Kwon JY; Kim M; Kim G; Kwon EJ; Lee HW; Noh M; Lee SK; Jeong LS
Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959689
[TBL] [Abstract][Full Text] [Related]
12. Posttranslational Modifications Pattern in Clear Cell Renal Cell Carcinoma.
Ene CD; Penescu MN; Georgescu SR; Tampa M; Nicolae I
Metabolites; 2020 Dec; 11(1):. PubMed ID: 33375435
[TBL] [Abstract][Full Text] [Related]
13. Human DNA Virus Exploitation of the MAPK-ERK Cascade.
DuShane JK; Maginnis MS
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336840
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation.
Sorokin M; Kholodenko R; Grekhova A; Suntsova M; Pustovalova M; Vorobyeva N; Kholodenko I; Malakhova G; Garazha A; Nedoluzhko A; Vasilov R; Poddubskaya E; Kovalchuk O; Adamyan L; Prassolov V; Allina D; Kuzmin D; Ignatev K; Osipov A; Buzdin A
Oncotarget; 2018 Jan; 9(4):5111-5124. PubMed ID: 29435166
[TBL] [Abstract][Full Text] [Related]
15. Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.
Gillissen B; Richter A; Richter A; Preissner R; Schulze-Osthoff K; Essmann F; Daniel PT
J Biol Chem; 2017 Apr; 292(16):6478-6492. PubMed ID: 28154184
[TBL] [Abstract][Full Text] [Related]
16. A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.
Kankanala J; Latham AM; Johnson AP; Homer-Vanniasinkam S; Fishwick CW; Ponnambalam S
Br J Pharmacol; 2012 May; 166(2):737-48. PubMed ID: 22141913
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling.
Maruwge W; D'Arcy P; Folin A; Brnjic S; Wejde J; Davis A; Erlandsson F; Bergh J; Brodin B
Onco Targets Ther; 2008 Nov; 1():67-78. PubMed ID: 21127754
[TBL] [Abstract][Full Text] [Related]
18. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
Valcamonico F; Ferrari V; Amoroso V; Rangoni G; Simoncini E; Marpicati P; Vassalli L; Grisanti S; Marini G
J Neurooncol; 2009 Jan; 91(1):47-50. PubMed ID: 18712279
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
Bracarda S; Caserta C; Sordini L; Rossi M; Hamzay A; Crinò L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi22-5. PubMed ID: 17591826
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
